Advances in non-dopaminergic treatments for Parkinson's disease

Frontiers in Neuroscience

Volumn , Issue 8 MAY, 2014, Pages

  Stayte, Sandy ^a,b   Vissel, Bryce ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Animal models; Dopamine; Dyskinesias; Gene therapy; L Dopa; Neurodegeneration; Parkinson's disease; Therapeutics

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5 PROPOXY 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDINE; 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; ADENOSINE RECEPTOR BLOCKING AGENT; ADRENERGIC RECEPTOR BLOCKING AGENT; AMPA RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; ANTIPARKINSON AGENT; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CALCIUM CHANNEL BLOCKING AGENT; CHELATING AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUTAMATE DECARBOXYLASE; ISTRADEFYLLINE; MAVOGLURANT; METABOTROPIC RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEURTURIN; SEROTONIN AGONIST; TRAXOPRODIL;

CLINICAL GENETICS; DRUG TARGETING; GENE THERAPY; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84904959625     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2014.00113     Document Type: Review

References (329)

1. Aarsland, D., Larsen, J. P., Lim, N. G., Janvin, C., Karlsen, K., Tandberg, E., et al. (1999). Range of neuropsychiatric disturbances in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 67, 492-496. doi: 10.1136/jnnp.67.4.492.
2. Abdipranoto-Cowley, A., Park, J. S., Croucher, D., Daniel, J., Henshall, S., Galbraith, S., et al. (2009). Activin A is essential for neurogenesis following neurodegeneration. Stem Cells 27, 1330-1346. doi: 10.1002/stem.80.
3. Albin, R. L., Young, A. B., and Penney, J. B. (1989). The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366-375. doi: 10.1016/0166-2236(89)90074-X.
4. Albin, R. L., Young, A. B., and Penney, J. B. (1995). The functional anatomy of disorders of the basal ganglia. Trends Neurosci. 18, 63-64. doi: 10.1016/0166-2236(95)80020-3.
5. Aldenkamp, A. P., Baker, G., Mulder, O. G., Chadwick, D., Cooper, P., Doelman, J., et al. (2000). A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 41, 1167-1178. doi: 10.1111/j.1528-1157.2000.tb00322.x.
6. Amgen. (2005). Following Complete Review of Phase 2 Trial Data Amgen Confirms Decision to Halt GDNF Study; Comprehensive Review of Scientific Findings, Patient Safety, Drove Decision. Thousand Oaks: AMGEN.
7. Amor, S., Puentes, F., Baker, D., and Van Der Valk, P. (2010). Inflammation in neurodegenerative diseases. Immunology 129, 154-169. doi: 10.1111/j.1365-2567.2009.03225.x.
8. Arai, R., Karasawa, N., Geffard, M., and Nagatsu, I. (1995). L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci. Lett. 195, 195-198. doi: 10.1016/0304-3940(95)11817-G.
9. Armentero, M. T., Fancellu, R., Nappi, G., Bramanti, P., and Blandini, F. (2006). Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Neurobiol. Dis. 22, 1-9. doi: 10.1016/j.nbd.2005.09.010.
10. Asanuma, M., and Miyazaki, I. (2007). Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease? Exp. Neurol. 206, 172-178. doi: 10.1016/j.expneurol.2007.05.006.
11. Attems, J., and Jellinger, K. A. (2008). The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease. Neuropathol. Appl. Neurobiol. 34, 466-467. doi: 10.1111/j.1365-2990.2008.00937.x.
12. Aubin, N., Curet, O., Deffois, A., and Carter, C. (1998). Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J. Neurochem. 71, 1635-1642. doi: 10.1046/j.1471-4159.1998.71041635.x.
13. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., et al. (2013). Exenatide and the treatment of patients with Parkinson's disease. J. Clin. Invest. 123, 2730-2736. doi: 10.1172/JCI68295.
14. Banati, R. B., Daniel, S. E., and Blunt, S. B. (1998). Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov. Disord. 13, 221-227. doi: 10.1002/mds.870130205.
15. Bara-Jimenez, W., Bibbiani, F., Morris, M. J., Dimitrova, T., Sherzai, A., Mouradian, M. M., et al. (2005). Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov. Disord. 20, 932-936. doi: 10.1002/mds.20370.
16. Bara-Jimenez, W., Sherzai, A., Dimitrova, T., Favit, A., Bibbiani, F., Gillespie, M., et al. (2003). Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 61, 293-296. doi: 10.1212/01.WNL.0000073136.00548.D4.
17. Barcia, C., Ros, C. M., Annese, V., Gomez, A., Ros-Bernal, F., Aguado-Yera, D., et al. (2011). IFN-gamma signaling, with the synergistic contribution of TNF-alpha, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell Death Dis. 2:e142. doi: 10.1038/cddis.2011.17.
18. Barnum, C. J., Bhide, N., Lindenbach, D., Surrena, M. A., Goldenberg, A. A., Tignor, S., et al. (2012). Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by alpha- and beta-adrenergic receptor antagonists in hemiparkinsonian rats. Pharmacol. Biochem. Behav. 100, 607-615. doi: 10.1016/j.pbb.2011.09.009.
19. Bartus, R. T., Baumann, T. L., Siffert, J., Herzog, C. D., Alterman, R., Boulis, N., et al. (2013). Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 80, 1698-1701. doi: 10.1212/WNL.0b013e3182904faa.
20. Bartus, R. T., Herzog, C. D., Chu, Y., Wilson, A., Brown, L., Siffert, J., et al. (2011). Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov. Disord. 26, 27-36. doi: 10.1002/mds.23442.
21. Beal, M. F. (2010). Parkinson's disease: a model dilemma. Nature 466, S8-S10. doi: 10.1038/466S8a.
22. Ben-Shachar, D., Eshel, G., Finberg, J. P., and Youdim, M. B. (1991). The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56, 1441-1444. doi: 10.1111/j.1471-4159.1991.tb11444.x.
23. Ben-Shachar, D., Eshel, G., Riederer, P., and Youdim, M. B. (1992). Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease. Ann. Neurol. 32(Suppl.), S105-S110. doi: 10.1002/ana.410320718.
24. Berg, D., Godau, J., Trenkwalder, C., Eggert, K., Csoti, I., Storch, A., et al. (2011). AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov. Disord. 26, 1243-1250. doi: 10.1002/mds.23616.
25. Berg, D., and Hochstrasser, H. (2006). Iron metabolism in Parkinsonian syndromes. Mov. Disord. 21, 1299-1310. doi: 10.1002/mds.21020.
26. Bezard, E., Tronci, E., Pioli, E. Y., Li, Q., Porras, G., Bjorklund, A., et al. (2013). Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov. Disord. 28, 1088-1096. doi: 10.1002/mds.25366.
27. Bishnoi, M., Chopra, K., and Kulkarni, S. K. (2006). Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur. J. Pharmacol. 552, 55-66. doi: 10.1016/j.ejphar.2006.09.010.
28. Bishnoi, M., Chopra, K., and Kulkarni, S. K. (2007). Theophylline, adenosine receptor antagonist prevents behavioral, biochemical and neurochemical changes associated with an animal model of tardive dyskinesia. Pharmacol. Rep. 59, 181-191..
29. Blanchet, P. J., Konitsiotis, S., Whittemore, E. R., Zhou, Z. L., Woodward, R. M., and Chase, T. N. (1999). Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther. 290, 1034-1040..
30. Blandini, F., Armentero, M. T., and Martignoni, E. (2008). The 6-hydroxydopamine model: news from the past. Parkinsonism. Relat. Disord. 14(Suppl. 2), S124-S129. doi: 10.1016/j.parkreldis.2008.04.015.
31. Blandini, F., Nappi, G., Tassorelli, C., and Martignoni, E. (2000). Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog. Neurobiol. 62, 63-88. doi: 10.1016/S0301-0082(99)00067-2.
32. Bonci, A., Grillner, P., Mercuri, N. B., and Bernardi, G. (1998). L-Type calcium channels mediate a slow excitatory synaptic transmission in rat midbrain dopaminergic neurons. J. Neurosci. 18, 6693-6703..
33. Bonifati, V., Fabrizio, E., Cipriani, R., Vanacore, N., and Meco, G. (1994). Buspirone in levodopa-induced dyskinesias. Clin. Neuropharmacol. 17, 73-82. doi: 10.1097/00002826-199402000-00008.
34. Boulet, S., Mounayar, S., Poupard, A., Bertrand, A., Jan, C., Pessiglione, M., et al. (2008). Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis. J. Neurosci. 28, 9575-9584. doi: 10.1523/JNEUROSCI.3465-08.2008.
35. Braak, H., Del Tredici, K., Bratzke, H., Hamm-Clement, J., Sandmann-Keil, D., and Rub, U. (2002). Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J. Neurol. 249(Suppl. 3), III, 1-5. doi: 10.1007/s00415-002-1301-4.
36. Braak, H., Del Tredici, K., Rub, U., De Vos, R. A., Jansen Steur, E. N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211. doi: 10.1016/S0197-4580(02)00065-9.
37. Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H., and Del Tredici, K. (2004). Stages in the development of Parkinson's disease-related pathology. Cell Tissue. Res. 318, 121-134. doi: 10.1007/s00441-004-0956-9.
38. Breysse, N., Amalric, M., and Salin, P. (2003). Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats. J. Neurosci. 23, 8302-8309..
39. Breysse, N., Baunez, C., Spooren, W., Gasparini, F., and Amalric, M. (2002). Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J. Neurosci. 22, 5669-5678.
40. Burchiel, K. J., Anderson, V. C., Favre, J., and Hammerstad, J. P. (1999). Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study. Neurosurgery 45, 1375-1382; discussion: 1382-1374..
41. Burn, D. J. (2002). Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov. Disord. 17, 445-454. doi: 10.1002/mds.10114.
42. Calne, D. B., and Zigmond, M. J. (1991). Compensatory mechanisms in degenerative neurologic diseases. Insights from parkinsonism. Arch. Neurol. 48, 361-363. doi: 10.1001/archneur.1991.00530160025009.
43. Calon, F., Dridi, M., Hornykiewicz, O., Bedard, P. J., Rajput, A. H., and Di Paolo, T. (2004). Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 127, 1075-1084. doi: 10.1093/brain/awh128.
44. Carlsson, M., and Carlsson, A. (1989). The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural. Transm. 75, 221-226. doi: 10.1007/BF01258633.
45. Carroll, R. C., and Zukin, R. S. (2002). NMDA-receptor trafficking and targeting: implications for synaptic transmission and plasticity. Trends. Neurosci. 25, 571-577. doi: 10.1016/S0166-2236(02)02272-5.
46. Carta, M., and Bezard, E. (2011). Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia. Neuroscience 198, 245-251. doi: 10.1016/j.neuroscience.2011.07.070.
47. Carta, M., Carlsson, T., Kirik, D., and Bjorklund, A. (2007). Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130, 1819-1833. doi: 10.1093/brain/awm082.
48. Ceregene (2013). Ceregene Reports Data from Parkinson's Disease Phase 2b Study. San Diego. Available online at: http://www.ceregene.com/press_041913.asp [Accessed 20 July 2013].
49. Chan, C. S., Gertler, T. S., and Surmeier, D. J. (2010). A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. Mov. Disord. 25(Suppl. 1), S63-S70. doi: 10.1002/mds.22801.
50. Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., et al. (2007). 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 447, 1081-1086. doi: 10.1038/nature05865.
51. Chen, J. F., Xu, K., Petzer, J. P., Staal, R., Xu, Y. H., Beilstein, M., et al. (2001). Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21, RC143..
52. Choi, D. W. (1988). Glutamate neurotoxicity and diseases of the nervous system. Neuron 1, 623-634. doi: 10.1016/0896-6273(88)90162-6.
53. Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., et al. (2009). Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73, 1662-1669. doi: 10.1212/WNL.0b013e3181c29356.
54. Cicchetti, F., Lapointe, N., Roberge-Tremblay, A., Saint-Pierre, M., Jimenez, L., Ficke, B. W., et al. (2005). Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats. Neurobiol. Dis. 20, 360-371. doi: 10.1016/j.nbd.2005.03.018.
55. Clark, I., Atwood, C., Bowen, R., Paz-Filho, G., and Vissel, B. (2012). Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales. Pharmacol. Rev. 64, 1004-1026. doi: 10.1124/pr.112.005850.
56. Clark, I. A., Alleva, L. M., and Vissel, B. (2010). The roles of TNF in brain dysfunction and disease. Pharmacol. Ther. 128, 519-548. doi: 10.1016/j.pharmthera.2010.08.007.
57. Clark, I. A., and Vissel, B. (2013). Treatment implications of the altered cytokine-insulin axis in neurodegenerative disease. Biochem. Pharmacol. 86, 862-871. doi: 10.1016/j.bcp.2013.07.030.
58. Coccurello, R., Breysse, N., and Amalric, M. (2004). Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology 29, 1451-1461. doi: 10.1038/sj.npp.1300444.
59. Collier, T. J., and Sortwell, C. E. (1999). Therapeutic potential of nerve growth factors in Parkinson's disease. Drugs Aging. 14, 261-287. doi: 10.2165/00002512-199914040-00003.
60. Conn, P. J., Battaglia, G., Marino, M. J., and Nicoletti, F. (2005). Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat. Rev. Neurosci. 6, 787-798. doi: 10.1038/nrn1763.
61. Corasaniti, M. T., Strongoli, M. C., Rotiroti, D., Bagetta, G., and Nistico, G. (1998). Paraquat: a useful tool for the in vivo study of mechanisms of neuronal cell death. Pharmacol. Toxicol. 83, 1-7. doi: 10.1111/j.1600-0773.1998.tb01434.x.
62. Cozzi, A., Rovelli, E., Frizzale, G., Campanella, A., Amendola, M., Arosio, P., et al. (2010). Oxidative stress and cell death in cells expressing L-ferritin variants causing neuroferritinopathy. Neurobiol. Dis. 37, 77-85. doi: 10.1016/j.nbd.2009.09.009.
63. Cummings, J., Isaacson, S., Mills, R., Williams, H., Chi-Burris, K., Corbett, A., et al. (2013). Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383, 533-540. doi: 10.1016/S0140-6736(13)62106-6.
64. Dauer, W., and Przedborski, S. (2003). Parkinson's disease: mechanisms and models. Neuron 39, 889-909. doi: 10.1016/S0896-6273(03)00568-3.
65. Dekundy, A., Pietraszek, M., Schaefer, D., Cenci, M. A., and Danysz, W. (2006). Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res. Bull. 69, 318-326. doi: 10.1016/j.brainresbull.2005.12.009.
66. Deng, X., Choi, H. G., Buhrlage, S. J., and Gray, N. S. (2012). Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011). Expert Opin. Ther. Pat. 22, 1415-1426. doi: 10.1517/13543776.2012.729041.
67. Derkach, V. A., Oh, M. C., Guire, E. S., and Soderling, T. R. (2007). Regulatory mechanisms of AMPA receptors in synaptic plasticity. Nat. Rev. Neurosci. 8, 101-113. doi: 10.1038/nrn2055.
68. Devos, D., Moreau, C., Devedjian, J. C., Kluza, J., Petrault, M., Laloux, C., et al. (2014). Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid. Redox. Signal. doi: 10.1089/ars.2013.5593. [Epub ahead of print]..
69. Dingledine, R., Borges, K., Bowie, D., and Traynelis, S. F. (1999). The glutamate receptor ion channels. Pharmacol. Rev. 51, 7-61..
70. Draganski, B., Kherif, F., Kloppel, S., Cook, P. A., Alexander, D. C., Parker, G. J., et al. (2008). Evidence for segregated and integrative connectivity patterns in the human Basal Ganglia. J. Neurosci. 28, 7143-7152. doi: 10.1523/JNEUROSCI.1486-08.2008.
71. Durif, F., Debilly, B., Galitzky, M., Morand, D., Viallet, F., Borg, M., et al. (2004). Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62, 381-388. doi: 10.1212/01.WNL.0000110317.52453.6C.
72. Durif, F., Vidailhet, M., Assal, F., Roche, C., Bonnet, A. M., and Agid, Y. (1997). Low-dose clozapine improves dyskinesias in Parkinson's disease. Neurology 48, 658-662. doi: 10.1212/WNL.48.3.658.
73. Dutra, R. C., Andreazza, A. P., Andreatini, R., Tufik, S., and Vital, M. A. (2002). Behavioral effects of MK-801 on reserpine-treated mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 26, 487-495. doi: 10.1016/S0278-5846(01)00295-0.
74. Duty, S., and Jenner, P. (2011). Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br. J. Pharmacol. 164, 1357-1391. doi: 10.1111/j.1476-5381.2011.01426.x.
75. Eberling, J. L., Kells, A. P., Pivirotto, P., Beyer, J., Bringas, J., Federoff, H. J., et al. (2009). Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum. Gene. Ther. 20, 511-518. doi: 10.1089/hum.2008.201.
76. Eggert, K., Squillacote, D., Barone, P., Dodel, R., Katzenschlager, R., Emre, M., et al. (2010). Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. Mov. Disord. 25, 896-905. doi: 10.1002/mds.22974.
77. El Yacoubi, M., Ledent, C., Menard, J. F., Parmentier, M., Costentin, J., and Vaugeois, J. M. (2000). The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors. Br. J. Pharmacol. 129, 1465-1473. doi: 10.1038/sj.bjp.0703170.
78. Emborg, M. E., Carbon, M., Holden, J. E., During, M. J., Ma, Y., Tang, C., et al. (2007). Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J. Cereb. Blood. Flow. Metab. 27, 501-509. doi: 10.1038/sj.jcbfm.9600364.
79. Emre, M. (2003). Dementia associated with Parkinson's disease. Lancet Neurol. 2, 229-237. doi: 10.1016/S1474-4422(03)00351-X.
80. Emre, M., Tsolaki, M., Bonuccelli, U., Destee, A., Tolosa, E., Kutzelnigg, A., et al. (2010). Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9, 969-977. doi: 10.1016/S1474-4422(10)70194-0.
81. Engber, T. M., Papa, S. M., Boldry, R. C., and Chase, T. N. (1994). NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 5, 2586-2588. doi: 10.1097/00001756-199412000-00045.
82. Erinoff, L., and Snodgrass, S. R. (1986). Effects of adult or neonatal treatment with 6-hydroxydopamine or 5,7-dihydroxytryptamine on locomotor activity, monoamine levels, and response to caffeine. Pharmacol. Biochem. Behav. 24, 1039-1045. doi: 10.1016/0091-3057(86)90453-3.
83. Eslamboli, A., Cummings, R. M., Ridley, R. M., Baker, H. F., Muzyczka, N., Burger, C., et al. (2003). Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp. Neurol. 184, 536-548. doi: 10.1016/j.expneurol.2003.08.007.
84. Factor, S., Mark, M. H., Watts, R., Struck, L., Mori, A., Ballerini, R., et al. (2010). A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. Parkinsonism. Relat. Disord. 16, 423-426. doi: 10.1016/j.parkreldis.2010.02.014.
85. Factor, S. A., Wolski, K., Togasaki, D. M., Huyck, S., Cantillon, M., Ho, T. W., et al. (2013). Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease. Mov. Disord. 28, 817-820. doi: 10.1002/mds.25395.
86. Fan, D. S., Ogawa, M., Fujimoto, K. I., Ikeguchi, K., Ogasawara, Y., Urabe, M., et al. (1998). Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum. Gene. Ther. 9, 2527-2535. doi: 10.1089/hum.1998.9.17-2527.
87. Ferger, B., Teismann, P., Earl, C. D., Kuschinsky, K., and Oertel, W. H. (1999). Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn. Schmiedebergs. Arch. Pharmacol. 360, 256-261. doi: 10.1007/s002109900079.
88. Fleming, S. M., Fernagut, P. O., and Chesselet, M. F. (2005). Genetic mouse models of parkinsonism: strengths and limitations. NeuroRx 2, 495-503. doi: 10.1602/neurorx.2.3.495.
89. Food and Drug Administration (2011). Azilect (Rasagiline Mesylate). Silver Spring, MD.
90. Fornai, F., Di Poggio, A. B., Pellegrini, A., Ruggieri, S., and Paparelli, A. (2007). Noradrenaline in Parkinson's disease: from disease progression to current therapeutics. Curr. Med. Chem. 14, 2330-2334. doi: 10.2174/092986707781745550.
91. Fox, S. H., Henry, B., Hill, M. P., Peggs, D., Crossman, A. R., and Brotchie, J. M. (2001). Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov. Disord. 16, 642-650. doi: 10.1002/mds.1148.
92. Gagne, J. J., and Power, M. C. (2010). Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 74, 995-1002. doi: 10.1212/WNL.0b013e3181d5a4a3.
93. Gal, S., Zheng, H., Fridkin, M., and Youdim, M. B. (2005). Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem. 95, 79-88. doi: 10.1111/j.1471-4159.2005.03341.x.
94. Gao, H. M., and Hong, J. S. (2008). Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends. Immunol. 29, 357-365. doi: 10.1016/j.it.2008.05.002.
95. Garcia-Borreguero, D., Larrosa, O., and Bravo, M. (2003). Parkinson's disease and sleep. Sleep. Med. Rev. 7, 115-129. doi: 10.1053/smrv.2002.0229.
96. Gasmi, M., Brandon, E. P., Herzog, C. D., Wilson, A., Bishop, K. M., Hofer, E. K., et al. (2007a). AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol. Dis. 27, 67-76. doi: 10.1016/j.nbd.2007.04.003.
97. Gasmi, M., Herzog, C. D., Brandon, E. P., Cunningham, J. J., Ramirez, G. A., Ketchum, E. T., et al. (2007b). Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol. Ther. 15, 62-68. doi: 10.1038/sj.mt.6300010.
98. Gerfen, C. R. (1992). The neostriatal mosaic: multiple levels of compartmental organization. Trends. Neurosci. 15, 133-139. doi: 10.1016/0166-2236(92)90355-C.
99. Gerhardt, G. A., Cass, W. A., Huettl, P., Brock, S., Zhang, Z., and Gash, D. M. (1999). GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys. Brain Res. 817, 163-171. doi: 10.1016/S0006-8993(98)01244-X.
100. Goetz, C. G., Damier, P., Hicking, C., Laska, E., Muller, T., Olanow, C. W., et al. (2007). Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov. Disord. 22, 179-186. doi: 10.1002/mds.21226.
101. Gomez-Mancilla, B., and Bedard, P. J. (1993). Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin. Neuropharmacol. 16, 418-427. doi: 10.1097/00002826-199310000-00004.
102. Graham, W. C., Robertson, R. G., Sambrook, M. A., and Crossman, A. R. (1990). Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism. Life Sci. 47, PL91-PL97. doi: 10.1016/0024-3205(90)90376-3.
103. Graybiel, A. M. (1990). Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13, 244-254. doi: 10.1016/0166-2236(90)90104-I.
104. Grunblatt, E., Mandel, S., Maor, G., and Youdim, M. B. (2001). Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J. Neurochem. 78, 1-12. doi: 10.1046/j.1471-4159.2001.00397.x.
105. Gryder, D. S., and Rogawski, M. A. (2003). Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J. Neurosci. 23, 7069-7074..
106. Hara, K., Tohyama, I., Kimura, H., Fukuda, H., Nakamura, S., and Kameyama, M. (1987). Reversible serotoninergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse striatum studied by neurochemical and immunohistochemical approaches. Brain Res. 410, 371-374. doi: 10.1016/0006-8993(87)90341-6.
107. Hardingham, G. E., and Bading, H. (2010). Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat. Rev. Neurosci. 11, 682-696. doi: 10.1038/nrn2911.
108. Harkavyi, A., Abuirmeileh, A., Lever, R., Kingsbury, A. E., Biggs, C. S., and Whitton, P. S. (2008). Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J. Neuroinflammation 5:19. doi: 10.1186/1742-2094-5-19.
109. Harman, D. (1972). The biologic clock: the mitochondria? J. Am. Geriatr. Soc. 20, 145-147..
110. Harms, A. S., Barnum, C. J., Ruhn, K. A., Varghese, S., Trevino, I., Blesch, A., et al. (2010). Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease. Mol. Ther. 19, 46-52. doi: 10.1038/mt.2010.217.
111. Hauser, R. A. (2009). Levodopa: past, present, and future. Eur. Neurol. 62, 1-8. doi: 10.1159/000215875.
112. Hauser, R. A., Cantillon, M., Pourcher, E., Micheli, F., Mok, V., Onofrj, M., et al. (2011). Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol. 10, 221-229. doi: 10.1016/S1474-4422(11)70012-6.
113. Hauser, R. A., Shulman, L. M., Trugman, J. M., Roberts, J. W., Mori, A., Ballerini, R., et al. (2008). Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov. Disord. 23, 2177-2185. doi: 10.1002/mds.22095.
114. Henry, B., Crossman, A. R., and Brotchie, J. M. (1998). Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 151, 334-342. doi: 10.1006/exnr.1998.6819.
115. Henry, B., Fox, S. H., Peggs, D., Crossman, A. R., and Brotchie, J. M. (1999). The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov. Disord. 14, 744-753..
116. Herzog, C. D., Dass, B., Holden, J. E., Stansell, J. 3rd. Gasmi, M., Tuszynski, M. H., et al. (2007). Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov. Disord. 22, 1124-1132. doi: 10.1002/mds.21503.
117. Hettinger, B. D., Lee, A., Linden, J., and Rosin, D. L. (2001). Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J. Comp. Neurol. 431, 331-346. doi: 10.1002/1096-9861(20010312)431:3%3C331::AID-CNE1074%3E3.0.CO;2-W.
118. Hill, M. P., and Brotchie, J. M. (1999). The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat. Br. J. Pharmacol. 128, 1577-1585. doi: 10.1038/sj.bjp.0702943.
119. Hirsch, E. C., Vyas, S., and Hunot, S. (2012). Neuroinflammation in Parkinson's disease. Parkinsonism. Relat. Disord. 18(Suppl. 1), S210-S212. doi: 10.1016/S1353-8020(11)70065-7.
120. Hodgson, R. A., Bertorelli, R., Varty, G. B., Lachowicz, J. E., Forlani, A., Fredduzzi, S., et al. (2009). Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. J. Pharmacol. Exp. Ther. 330, 294-303. doi: 10.1124/jpet.108.149617.
121. Hollmann, M., and Heinemann, S. (1994). Cloned glutamate receptors. Annu. Rev. Neurosci. 17, 31-108. doi: 10.1146/annurev.ne.17.030194.000335.
122. Huang, Z. L., Qu, W. M., Eguchi, N., Chen, J. F., Schwarzschild, M. A., Fredholm, B. B., et al. (2005). Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat. Neurosci. 8, 858-859. doi: 10.1038/nn1491.
123. Huot, P., Johnston, T. H., Lewis, K. D., Koprich, J. B., Reyes, M. G., Fox, S. H., et al. (2014). UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances l-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. Neuropharmacology 82C, 76-87. doi: 10.1016/j.neuropharm.2014.01.012.
124. Ikeda, K., Kurokawa, M., Aoyama, S., and Kuwana, Y. (2002). Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J. Neurochem. 80, 262-270. doi: 10.1046/j.0022-3042.2001.00694.x.
125. Ilijic, E., Guzman, J. N., and Surmeier, D. J. (2011). The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol. Dis. 43, 364-371. doi: 10.1016/j.nbd.2011.04.007.
126. Invernizzi, R. W., Garavaglia, C., and Samanin, R. (2003). The alpha 2-adrenoceptor antagonist idazoxan reverses catalepsy induced by haloperidol in rats independent of striatal dopamine release: role of serotonergic mechanisms. Neuropsychopharmacology 28, 872-879. doi: 10.1038/sj.npp.13001191300119.
127. Ishiwata, K., Mishina, M., Kimura, Y., Oda, K., Sasaki, T., and Ishii, K. (2005). First visualization of adenosine A(2A) receptors in the human brain by positron emission tomography with [11C]TMSX. Synapse 55, 133-136. doi: 10.1002/syn.20099.
128. Jackson-Lewis, V., Blesa, J., and Przedborski, S. (2012). Animal models of Parkinson's disease. Parkinsonism. Relat. Disord. 18 (Suppl. 1), S183-S185. doi: 10.1016/S1353-8020(11)70057-8.
129. Jellinger, K. A. (2009). A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim. Biophys. Acta 1792, 730-740. doi: 10.1016/j.bbadis.2008.07.006.
130. Jenner, P., Mori, A., Hauser, R., Morelli, M., Fredholm, B. B., and Chen, J. F. (2009). Adenosine, adenosine A 2A antagonists, and Parkinson's disease. Parkinsonism. Relat. Disord. 15, 406-413. doi: 10.1016/j.parkreldis.2008.12.006.
131. Johnston, L. C., Eberling, J., Pivirotto, P., Hadaczek, P., Federoff, H. J., Forsayeth, J., et al. (2009). Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum. Gene. Ther. 20, 497-510. doi: 10.1089/hum.2008.137.
132. Johnston, T. H., Fox, S. H., Piggott, M. J., Savola, J. M., and Brotchie, J. M. (2010). The alpha(2) adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. Mov. Disord. 25, 2084-2093. doi: 10.1002/mds.23172.
133. Kachroo, A., Irizarry, M. C., and Schwarzschild, M. A. (2010). Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Exp. Neurol. 223, 657-661. doi: 10.1016/j.expneurol.2010.02.007.
134. Kachroo, A., Orlando, L. R., Grandy, D. K., Chen, J. F., Young, A. B., and Schwarzschild, M. A. (2005). Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J. Neurosci. 25, 10414-10419. doi: 10.1523/JNEUROSCI.3660-05.2005.
135. Kalda, A., Yu, L., Oztas, E., and Chen, J. F. (2006). Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease. J. Neurol. Sci. 248, 9-15. doi: 10.1016/j.jns.2006.05.003.
136. Kanda, T., Jackson, M. J., Smith, L. A., Pearce, R. K., Nakamura, J., Kase, H., et al. (1998). Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 43, 507-513. doi: 10.1002/ana.410430415.
137. Kang, S., Cooper, G., Dunne, S. F., Dusel, B., Luan, C. H., and Surmeier, D. J. (2012). CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Nat. Commun. 3, 1146. doi: 10.1038/ncomms2149.
138. Kannari, K., Kurahashi, K., Tomiyama, M., Maeda, T., Arai, A., Baba, M., et al. (2002). [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease]. Shinkei. 54, 133-137.
139. Kanner, A. M., Wuu, J., Faught, E., Tatum, W. O. T., Fix, A., and French, J. A. (2003). A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy. Behav. 4, 548-552. doi: 10.1016/j.yebeh.2003.07.007.
140. Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., et al. (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369, 2097-2105. doi: 10.1016/S0140-6736(07)60982-9.
141. Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., et al. (2003). Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37, 899-909. doi: 10.1016/S0896-6273(03)00126-0.
142. Kaur, S., Ozer, H., and Starr, M. (1997). MK 801 reverses haloperidol-induced catalepsy from both striatal and extrastriatal sites in the rat brain. Eur. J. Pharmacol. 332, 153-160. doi: 10.1016/S0014-2999(97)01078-9.
143. Kaur, S., and Starr, M. S. (1995). Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse. Eur. J. Pharmacol. 280, 159-166. doi: 10.1016/0014-2999(95)00200-5.
144. Kearney, J. A., Becker, J. B., Frey, K. A., and Albin, R. L. (1998). The role of nigrostriatal dopamine in metabotropic glutamate agonist-induced rotation. Neuroscience 87, 881-891..
145. Kearney, J. A., Frey, K. A., and Albin, R. L. (1997). Metabotropic glutamate agonist-induced rotation: a pharmacological, FOS immunohistochemical, and [14C]-2-deoxyglucose autoradiographic study. J. Neurosci. 17, 4415-4425..
146. Kelsey, J. E., Mague, S. D., Pijanowski, R. S., Harris, R. C., Kleckner, N. W., and Matthews, R. T. (2004). NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats. Psychopharmacology (Berl.) 175, 179-188. doi: 10.1007/s00213-004-1799-5.
147. Kessels, H. W., and Malinow, R. (2009). Synaptic AMPA receptor plasticity and behavior. Neuron 61, 340-350. doi: 10.1016/j.neuron.2009.01.015.
148. Kirik, D., Rosenblad, C., and Bjorklund, A. (2000a). Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur. J. Neurosci. 12, 3871-3882. doi: 10.1046/j.1460-9568.2000.00274.x.
149. Kirik, D., Rosenblad, C., Bjorklund, A., and Mandel, R. J. (2000b). Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci. 20, 4686-4700..
150. Kish, S. J. (2003). Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease? Adv. Neurol. 91, 39-49..
151. Klein, C., and Westenberger, A. (2012). Genetics of Parkinson's disease. Cold. Spring. Harb. Perspect. Med. 2:a008888. doi: 10.1101/cshperspect.a008888.
152. Klockgether, T., Turski, L., Honore, T., Zhang, Z. M., Gash, D. M., Kurlan, R., et al. (1991). The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol. 30, 717-723. doi: 10.1002/ana.410300513.
153. Knott, C., Stern, G., and Wilkin, G. P. (2000). Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell Neurosci. 16, 724-739. doi: 10.1006/mcne.2000.0914.
154. Kobylecki, C., Burn, D. J., Kass-Iliyya, L., Kellett, M. W., Crossman, A. R., and Silverdale, M. A. (2014). Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease. Parkinsonism. Relat. Disord. 240, 452-455. doi: 10.1016/j.parkreldis.2014.01.016.
155. Kobylecki, C., Hill, M. P., Crossman, A. R., and Ravenscroft, P. (2011). Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease. Mov. Disord. 26, 2354-2363. doi: 10.1002/mds.23867.
156. Konieczny, J., Ossowska, K., Schulze, G., Coper, H., and Wolfarth, S. (1999). L-701,324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats. Psychopharmacology (Berl.) 143, 235-243. doi: 10.1007/s002130050942.
157. Konitsiotis, S., Blanchet, P. J., Verhagen, L., Lamers, E., and Chase, T. N. (2000). AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology. 54, 1589-1595. doi: 10.1212/WNL.54.8.1589.
158. Kordower, J. H., Herzog, C. D., Dass, B., Bakay, R. A., Stansell, J. 3rd. Gasmi, M., et al. (2006). Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann. Neurol. 60, 706-715. doi: 10.1002/ana.21032.
159. Kordower, J. H., Palfi, S., Chen, E. Y., Ma, S. Y., Sendera, T., Cochran, E. J., et al. (1999). Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. 46, 419-424..
160. Kotzbauer, P. T., Lampe, P. A., Heuckeroth, R. O., Golden, J. P., Creedon, D. J., Johnson, E. M. Jr., et al. (1996). Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 384, 467-470. doi: 10.1038/384467a0.
161. Koutsilieri, E., and Riederer, P. (2007). Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease. Parkinsonism. Relat. Disord. 13(Suppl. 3), S329-S331. doi: 10.1016/S1353-8020(08)70025-7.
162. Kravitz, A. V., Freeze, B. S., Parker, P. R., Kay, K., Thwin, M. T., Deisseroth, K., et al. (2010). Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 466, 622-626. doi: 10.1038/nature09159.
163. Kumar, R., Lozano, A. M., Kim, Y. J., Hutchison, W. D., Sime, E., Halket, E., et al. (1998). Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology 51, 850-855. doi: 10.1212/WNL.51.3.850.
164. Kurkowska-Jastrzebska, I., Babiuch, M., Joniec, I., Przybylkowski, A., Czlonkowski, A., and Czlonkowska, A. (2002). Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice. Int. Immunopharmacol. 2, 1213-1218. doi: 10.1016/S1567-5769(02)00078-4.
165. Kuwajima, M., Dehoff, M. H., Furuichi, T., Worley, P. F., Hall, R. A., and Smith, Y. (2007). Localization and expression of group I metabotropic glutamate receptors in the mouse striatum, globus pallidus, and subthalamic nucleus: regulatory effects of MPTP treatment and constitutive Homer deletion. J. Neurosci. 27, 6249-6260. doi: 10.1523/JNEUROSCI.3819-06.2007.
166. Kyowa Hakko Kirin Co Ltd. (2008). Kyowa Hakko Receives Not Approvable Letter from FDA for Istradefylline (KW-6002) [Media Release]. Available online at: http://www.kyowa-kirin.com/news_releases/kyowa/2008/er080228_01.html [Accessed 10 December 2013].
167. Kyowa Hakko Kirin Co Ltd. (2013). Approval for Manufacturing and Marketing of NOURIAST Tablets 20 mg, a Novel Antiparkinsonian Agent [Media Release]. Available online: http://www.kyowa-kirin.com/news_releases/2013/e20130325_04.html [Accessed 10 December 2013].
168. Lan, J., and Jiang, D. H. (1997). Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural. Transm. 104, 469-481. doi: 10.1007/BF01277665.
169. Lange, K. W., Loschmann, P. A., Sofic, E., Burg, M., Horowski, R., Kalveram, K. T., et al. (1993). The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates. Naunyn. Schmiedebergs. Arch. Pharmacol. 348, 586-592. doi: 10.1007/BF00167234.
170. Latini, S., and Pedata, F. (2001). Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J. Neurochem 79, 463-484. doi: 10.1046/j.1471-4159.2001.00607.x.
171. Lau, C. G., and Zukin, R. S. (2007). NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat. Rev. Neurosci. 8, 413-426. doi: 10.1038/nrn2153.
172. Lavoie, B., and Parent, A. (1990). Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J. Comp. Neurol. 299, 1-16. doi: 10.1002/cne.902990102.
173. Lee, B., Lee, H., Nam, Y. R., Oh, J. H., Cho, Y. H., and Chang, J. W. (2005). Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models. Gene. Ther. 12, 1215-1222. doi: 10.1038/sj.gt.3302520.
174. Lees, A., Fahn, S., Eggert, K. M., Jankovic, J., Lang, A., Micheli, F., et al. (2012). Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov. Disord. 27, 284-288. doi: 10.1002/mds.23983.
175. Leff, S. E., Spratt, S. K., Snyder, R. O., and Mandel, R. J. (1999). Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease. Neuroscience 92, 185-196. doi: 10.1016/S0306-4522(98)00741-6.
176. Lewitt, P. A., Guttman, M., Tetrud, J. W., Tuite, P. J., Mori, A., Chaikin, P., et al. (2008). Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann. Neurol. 63, 295-302. doi: 10.1002/ana.21315.
177. Lewitt, P. A., Hauser, R. A., Lu, M., Nicholas, A. P., Weiner, W., Coppard, N., et al. (2012). Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 79, 163-169. doi: 10.1212/WNL.0b013e31825f0451.
178. Lewitt, P. A., Li, J., Lu, M., Beach, T. G., Adler, C. H., and Guo, L. (2013). 3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis. Mov. Disord. 28, 1653-1660. doi: 10.1002/mds.25555.
179. Lewitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., et al. (2011). AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 10, 309-319. doi: 10.1016/S1474-4422(11)70039-4.
180. Li, X., Jankovic, J., and Le, W. (2011). Iron chelation and neuroprotection in neurodegenerative diseases. J. Neural. Transm. 118, 473-477. doi: 10.1007/s00702-010-0518-0.
181. Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., et al. (2009). GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. U.S.A. 106, 1285-1290. doi: 10.1073/pnas.0806720106.
182. Lin, L. F., Doherty, D. H., Lile, J. D., Bektesh, S., and Collins, F. (1993). GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260, 1130-1132. doi: 10.1126/science.8493557.
183. Lin, S. C., Lin, K. J., Hsiao, I. T., Hsieh, C. J., Lin, W. Y., Lu, C. S., et al. (2013). In vivo detection of monoaminergic degeneration in early Parkinson disease by 18F-9-Fluoropropyl-(+)-Dihydrotetrabenzazine PET. J. Nucl. Med. 55, 73-79. doi: 10.2967/jnumed.113.121897.
184. Lindgren, H. S., Andersson, D. R., Lagerkvist, S., Nissbrandt, H., and Cenci, M. A. (2010). L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J. Neurochem. 112, 1465-1476. doi: 10.1111/j.1471-4159.2009.06556.x.
185. Lipscombe, D., Helton, T. D., and Xu, W. (2004). L-type calcium channels: the low down. J. Neurophysiol. 92, 2633-2641. doi: 10.1152/jn.00486.2004.
186. Loschmann, P. A., Kunow, M., and Wachtel, H. (1992). Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease. J. Neural. Transm. Suppl. 38, 55-64..
187. Loschmann, P. A., Lange, K. W., Kunow, M., Rettig, K. J., Jahnig, P., Honore, T., et al. (1991). Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease. J. Neural. Transm. Park. Dis. Dement. Sect. 3, 203-213. doi: 10.1007/BF02259538.
188. Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O'Brien, P., and Trojanowski, J. Q. (2012). Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949-953. doi: 10.1126/science.1227157.
189. Luo, J., Kaplitt, M. G., Fitzsimons, H. L., Zuzga, D. S., Liu, Y., Oshinsky, M. L., et al. (2002). Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298, 425-429. doi: 10.1126/science.1074549.
190. Magerkurth, C., Schnitzer, R., and Braune, S. (2005). Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life. Clin. Auton. Res. 15, 76-82. doi: 10.1007/s10286-005-0253-z.
191. Mandhane, S. N., Chopde, C. T., and Ghosh, A. K. (1997). Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats. Eur. J. Pharmacol. 328, 135-141. doi: 10.1016/S0014-2999(97)83039-7.
192. Marin, C., Papa, S., Engber, T. M., Bonastre, M., Tolosa, E., and Chase, T. N. (1996). MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res. 736, 202-205. doi: 10.1016/0006-8993(96)00693-2.
193. Marinova-Mutafchieva, L., Sadeghian, M., Broom, L., Davis, J. B., Medhurst, A. D., and Dexter, D. T. (2009). Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease. J. Neurochem. 110, 966-975. doi: 10.1111/j.1471-4159.2009.06189.x.
194. Marks, W. J. Jr. Bartus, R. T., Siffert, J., Davis, C. S., Lozano, A., Boulis, N., et al. (2010). Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 9, 1164-1172. doi: 10.1016/S1474-4422(10)70254-4.
195. Marks, W. J. Jr. Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., et al. (2008). Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 7, 400-408. doi: 10.1016/S1474-4422(08)70065-6.
196. Marsala, S. Z., Gioulis, M., Ceravolo, R., and Tinazzi, M. (2012). A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice. Clin. Neuropharmacol. 35, 185-190. doi: 10.1097/WNF.0b013e31825c034a.
197. Mastroberardino, P. G., Hoffman, E. K., Horowitz, M. P., Betarbet, R., Taylor, G., Cheng, D., et al. (2009). A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol. Dis. 34, 417-431. doi: 10.1016/j.nbd.2009.02.009.
198. Mavridis, M., Degryse, A. D., Lategan, A. J., Marien, M. R., and Colpaert, F. C. (1991). Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 41, 507-523. doi: 10.1016/0306-4522(91)90345-O.
199. McAllister, K. H. (1996). The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats. Eur. J. Pharmacol. 314, 307-311. doi: 10.1016/S0014-2999(96)00576-6.
200. Mcgeer, P. L., Itagaki, S., Boyes, B. E., and Mcgeer, E. G. (1988). Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38, 1285-1291. doi: 10.1212/WNL.38.8.1285.
201. Mcgeer, P. L., Schwab, C., Parent, A., and Doudet, D. (2003). Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann. Neurol. 54, 599-604. doi: 10.1002/ana.10728.
202. Mcmillan, P. J., White, S. S., Franklin, A., Greenup, J. L., Leverenz, J. B., Raskind, M. A., et al. (2011). Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease. Brain Res. 1373, 240-252. doi: 10.1016/j.brainres.2010.12.015.
203. Meco, G., Fabrizio, E., Di Rezze, S., Alessandri, A., and Pratesi, L. (2003). Mirtazapine in L-dopa-induced dyskinesias. Clin. Neuropharmacol. 26, 179-181. doi: 10.1097/00002826-200307000-00005.
204. Meco, G., Stirpe, P., Edito, F., Purcaro, C., Valente, M., Bernardi, S., et al. (2009). Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study. J. Neural. Transm. 116, 881-884. doi: 10.1007/s00702-009-0231-z.
205. Mehta, A. K., and Ticku, M. K. (1990). Role of N-methyl-D-aspartate (NMDA) receptors in experimental catalepsy in rats. Life Sci. 46, 37-42. doi: 10.1016/0024-3205(90)90054-U.
206. Melrose, H. L., Lincoln, S. J., Tyndall, G. M., and Farrer, M. J. (2006). Parkinson's disease: a rethink of rodent models. Exp. Brain Res. 173, 196-204. doi: 10.1007/s00221-006-0461-3.
207. Mertens, J., Stuber, K., Wunderlich, P., Ladewig, J., Kesavan, J. C., Vandenberghe, R., et al. (2013). APP Processing in human pluripotent stem cell-derived neurons is resistant to NSAID-based gamma-secretase modulation. Stem. Cell. Reports 1, 491-498. doi: 10.1016/j.stemcr.2013.10.011.
208. Michael, J. Fox Foundation. (2014). Drug that May Slow Parkinson's Progression Granted $23 Million from NIH for Phase III testing. New York, NY: Michael J. Fox Foundation. Available online at: https://www.michaeljfox.org/foundation/news-detail.php?podcast-drug-that-may-slow-parkinson-progression-granted-23-million-from-nih-for-phase-iii [Accessed 4 April 2014].
209. Michael, J. Fox Foundation. (2012). Addex Adds it Up for Parkinson's Patients. New York, NY: The Michael J. Fox Foundation.
210. Mirza, B., Hadberg, H., Thomsen, P., and Moos, T. (2000). The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 95, 425-432. doi: 10.1016/S0306-4522(99)00455-8.
211. Mitra, S., Chakrabarti, N., and Bhattacharyya, A. (2011). Differential regional expression patterns of alpha-synuclein, TNF-alpha, and IL-1beta ; and variable status of dopaminergic neurotoxicity in mouse brain after Paraquat treatment. J. Neuroinflammation. 8:163. doi: 10.1186/1742-2094-8-163.
212. Mittermeyer, G., Christine, C. W., Rosenbluth, K. H., Baker, S. L., Starr, P., Larson, P., et al. (2014). Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum. Gene. Ther. 23, 377-381. doi: 10.1089/hum.2011.220.
213. Miyasaki, J. M. (2010). Evidence-based initiation of dopaminergic therapy in Parkinson's disease. J. Neurol. 257, S309-S313. doi: 10.1007/s00415-010-5718-x.
214. Miyoshi, Y., Zhang, Z., Ovadia, A., Lapchak, P. A., Collins, F., Hilt, D., et al. (1997). Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. Ann. Neurol. 42, 208-214. doi: 10.1002/ana.410420212.
215. Mizuno, Y., and Kondo, T. (2013). Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Mov. Disord. 28, 1138-1141. doi: 10.1002/mds.25418.
216. Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., et al. (1994). Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180, 147-150. doi: 10.1016/0304-3940(94)90508-8.
217. Mollenhauer, B., Trautmann, E., Taylor, P., Manninger, P., Sixel-Doring, F., Ebentheuer, J., et al. (2013). Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci. Lett. 532, 44-48. doi: 10.1016/j.neulet.2012.11.004.
218. Moreau, C., Delval, A., Tiffreau, V., Defebvre, L., Dujardin, K., Duhamel, A., et al. (2013). Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study. J. Neurol. Neurosurg. Psychiatry. 84, 552-555. doi: 10.1136/jnnp-2012-303182.
219. Morin, N., Gregoire, L., Morissette, M., Desrayaud, S., Gomez-Mancilla, B., Gasparini, F., et al. (2013a). MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates. Neuropharmacology 66, 355-364. doi: 10.1016/j.neuropharm.2012.07.036.
220. Morin, N., Morissette, M., Gregoire, L., Gomez-Mancilla, B., Gasparini, F., and Di Paolo, T. (2013b). Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys. Neuropharmacology 73C, 216-231. doi: 10.1016/j.neuropharm.2013.05.028.
221. Morris, G. P., Clark, I. A., Zinn, R., and Vissel, B. (2013). Microglia: a new frontier for synaptic plasticity, learning and memory, and neurodegenerative disease research. Neurobiol. Learn. Mem. 105, 40-53. doi: 10.1016/j.nlm.2013.07.002.
222. Munoz, A., Li, Q., Gardoni, F., Marcello, E., Qin, C., Carlsson, T., et al. (2008). Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 131, 3380-3394. doi: 10.1093/brain/awn235.
223. Muramatsu, S., Fujimoto, K., Kato, S., Mizukami, H., Asari, S., Ikeguchi, K., et al. (2010). A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol. Ther. 18, 1731-1735. doi: 10.1038/mt.2010.135.
224. Nash, J. E., Fox, S. H., Henry, B., Hill, M. P., Peggs, D., Mcguire, S., et al. (2000). Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. 165, 136-142. doi: 10.1006/exnr.2000.7444.
225. Niswender, C. M., and Conn, P. J. (2010). Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 50, 295-322. doi: 10.1146/annurev.pharmtox.011008.145533.
226. Nowak, P., Bortel, A., Dabrowska, J., Biedka, I., Slomian, G., Roczniak, W., et al. (2008). Histamine H(3) receptor ligands modulate L-dopa-evoked behavioral responses and L-dopa derived extracellular dopamine in dopamine-denervated rat striatum. Neurotox. Res. 13, 231-240. doi: 10.1007/BF03033506.
227. Nutt, J. G., Burchiel, K. J., Comella, C. L., Jankovic, J., Lang, A. E., Laws, E. R. Jr., et al. (2003). Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60, 69-73. doi: 10.1212/WNL.60.1.69.
228. Oiwa, Y., Yoshimura, R., Nakai, K., and Itakura, T. (2002). Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease. Brain Res. 947, 271-283. doi: 10.1016/S0006-8993(02)02934-7.
229. Olanow, C. W., Damier, P., Goetz, C. G., Mueller, T., Nutt, J., Rascol, O., et al. (2004). Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin. Neuropharmacol. 27, 58-62. doi: 10.1097/00002826-200403000-00003.
230. Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., et al. (2009). A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 361, 1268-1278. doi: 10.1056/NEJMoa0809335.
231. Oliveira, S. A., Scott, W. K., Martin, E. R., Nance, M. A., Watts, R. L., Hubble, et al. (2003). Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann. Neurol. 53, 624-629. doi: 10.1002/ana.10524.
232. Palfi, S., Gurruchaga, J. M., Ralph, G. S., Lepetit, H., Lavisse, S., Buttery, P. C., et al. (2014). Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 383, 1138-1146. doi: 10.1016/S0140-6736(13)61939-X.
233. Palfi, S., Leventhal, L., Chu, Y., Ma, S. Y., Emborg, M., Bakay, R., et al. (2002). Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J. Neurosci. 22, 4942-4954..
234. Paoletti, P., Bellone, C., and Zhou, Q. (2013). NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat. Rev. Neurosci. 14, 383-400. doi: 10.1038/nrn3504.
235. Paoletti, P., and Neyton, J. (2007). NMDA receptor subunits: function and pharmacology. Curr. Opin. Pharmacol. 7, 39-47. doi: 10.1016/j.coph.2006.08.011.
236. Parkinson Study Group. (1989). Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N. Engl. J. Med. 321, 1364-1371. doi: 10.1056/NEJM198911163212004.
237. Parkinson Study Group. (1993). Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328, 176-183. doi: 10.1056/NEJM199301213280305.
238. Parkinson Study Group. (2004). A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61, 561-566. doi: 10.1001/archneur.61.4.561.
239. Parkinson Study Group (2013). Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Mov. Disord. 28, 1823-1831. doi: 10.1002/mds.25639.
240. Parkkinen, L., Pirttila, T., and Alafuzoff, I. (2008). Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta. Neuropathol. 115, 399-407. doi: 10.1007/s00401-008-0346-6.
241. Parnetti, L., Castrioto, A., Chiasserini, D., Persichetti, E., Tambasco, N., El-Agnaf, O., et al. (2013). Cerebrospinal fluid biomarkers in Parkinson disease. Nat. Rev. Neurol. 9, 131-140. doi: 10.1038/nrneurol.2013.10.
242. Perez-Lloret, S., and Rascol, O. (2010). Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease. CNS Drugs 24, 941-968. doi: 10.2165/11537810-000000000-00000.
243. Perez-Otano, I., and Ehlers, M. D. (2005). Homeostatic plasticity and NMDA receptor trafficking. Trends. Neurosci. 28, 229-238. doi: 10.1016/j.tins.2005.03.004.
244. Peroutka, S. J. (1995). 5-HT receptors: past, present and future. Trends. Neurosci. 18, 68-69. doi: 10.1016/0166-2236(95)80023-U.
245. Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., and Greig, N. H. (2002a). Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol. Exp. Ther. 302, 881-888. doi: 10.1124/jpet.102.037481.
246. Perry, T., Lahiri, D. K., Chen, D., Zhou, J., Shaw, K. T., Egan, J. M., et al. (2002b). A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 300, 958-966. doi: 10.1124/jpet.300.3.958.
247. Phani, S., Loike, J. D., and Przedborski, S. (2012). Neurodegeneration and inflammation in Parkinson's disease. Parkinsonism. Relat. Disord. 18(Suppl. 1), S207-S209. doi: 10.1016/S1353-8020(11)70064-5.
248. Phinney, A. L., Andringa, G., Bol, J. G., Wolters, E., Van Muiswinkel, F. L., Van Dam, A. M., et al. (2006). Enhanced sensitivity of dopaminergic neurons to rotenone-induced toxicity with aging. Parkinsonism. Relat. Disord. 12, 228-238. doi: 10.1016/j.parkreldis.2005.12.002.
249. Porter, R. H., Greene, J. G., Higgins, D. S. Jr., and Greenamyre, J. T. (1994). Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion. J. Neurosci. 14, 7192-7199..
250. Potashkin, J. A., Blume, S. R., and Runkle, N. K. (2011). Limitations of animal models of Parkinson's disease. Parkinsons. Dis. 2011:658083. doi: 10.4061/2011/658083.
251. Price, D. L., Rockenstein, E., Ubhi, K., Phung, V., Maclean-Lewis, N., Askay, D., et al. (2010). Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy-implications for excitotoxicity. PLoS ONE 5:e14020. doi: 10.1371/journal.pone.0014020.
252. Przedborski, S., Tieu, K., Perier, C., and Vila, M. (2004). MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J. Bioenerg. Biomembr. 36, 375-379. doi: 10.1023/B:JOBB.0000041771.66775.d5.
253. Przedborski, S., and Vila, M. (2003). The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann. N.Y. Acad. Sci. 991, 189-198. doi: 10.1111/j.1749-6632.2003.tb07476.x.
254. Rascol, O., Arnulf, I., Peyro-Saint Paul, H., Brefel-Courbon, C., Vidailhet, M., Thalamas, C., et al. (2001). Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov. Disord. 16, 708-713. doi: 10.1002/mds.1143.
255. Rascol, O., Barone, P., Behari, M., Emre, M., Giladi, N., Olanow, C. W., et al. (2012). Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clin. Neuropharmacol. 35, 15-20. doi: 10.1097/WNF.0b013e318241520b.
256. Reale, M., Iarlori, C., Thomas, A., Gambi, D., Perfetti, B., Di Nicola, M., et al. (2009). Peripheral cytokines profile in Parkinson's disease. Brain Behav. Immun. 23, 55-63. doi: 10.1016/j.bbi.2008.07.003.
257. Redgrave, P., Rodriguez, M., Smith, Y., Rodriguez-Oroz, M. C., Lehericy, S., Bergman, H., et al. (2010). Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nat. Rev. Neurosci. 11, 760-772. doi: 10.1038/nrn2915.
258. Rees, K., Stowe, R., Patel, S., Ives, N., Breen, K., Ben-Shlomo, Y., et al. (2011). Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies and clinical trials. Cochrane. Database. Syst. Rev. 11:CD008535. doi: 10.1002/14651858.CD008535.
259. Ren, X., Zhang, T., Gong, X., Hu, G., Ding, W., and Wang, X. (2013). AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model. Exp. Neurol. 248, 148-156. doi: 10.1016/j.expneurol.2013.06.002.
260. Rodnitzky, R. L. (1999). Can calcium antagonists provide a neuroprotective effect in Parkinson's disease? Drugs 57, 845-849. doi: 10.2165/00003495-199957060-00001.
261. Rommelfanger, K. S., Edwards, G. L., Freeman, K. G., Liles, L. C., Miller, G. W., and Weinshenker, D. (2007). Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc. Natl. Acad. Sci. U.S.A. 104, 13804-13809. doi: 10.1073/pnas.0702753104.
262. Rosenblad, C., Kirik, D., Devaux, B., Moffat, B., Phillips, H. S., and Bjorklund, A. (1999). Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur. J. Neurosci. 11, 1554-1566. doi: 10.1046/j.1460-9568.1999.00566.x.
263. Rousselet, E., Joubert, C., Callebert, J., Parain, K., Tremblay, L., Orieux, G., et al. (2003). Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice. Neurobiol. Dis. 14, 218-228. doi: 10.1016/S0969-9961(03)00108-6.
264. Ryczko, D., Gratsch, S., Auclair, F., Dube, C., Bergeron, S., Alpert, M. H., et al. (2013). Forebrain dopamine neurons project down to a brainstem region controlling locomotion. Proc. Natl. Acad. Sci. U.S.A. 110, E3235-E3242. doi: 10.1073/pnas.1301125110.
265. Rylander, D., Recchia, A., Mela, F., Dekundy, A., Danysz, W., and Cenci, M. A. (2009). Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J. Pharmacol. Exp. Ther. 330, 227-235. doi: 10.1124/jpet.108.150425.
266. Salamone, J. D., Betz, A. J., Ishiwari, K., Felsted, J., Madson, L., Mirante, B., et al. (2008). Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism. Front. Biosci. 13, 3594-3605. doi: 10.2741/2952.
267. Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., et al. (2014). Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 322-333. doi: 10.1056/NEJMoa1304839.
268. Samadi, P., Gregoire, L., Morissette, M., Calon, F., Hadj Tahar, A., Dridi, M., et al. (2008). mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol. Aging 29, 1040-1051. doi: 10.1016/j.neurobiolaging.2007.02.005.
269. Sanchez-Pernaute, R., Ferree, A., Cooper, O., Yu, M., Brownell, A. L., and Isacson, O. (2004). Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J. Neuroinflammation. 1:6. doi: 10.1186/1742-2094-1-6.
270. Sanchez-Pernaute, R., Harvey-White, J., Cunningham, J., and Bankiewicz, K. S. (2001). Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. Mol. Ther. 4, 324-330. doi: 10.1006/mthe.2001.0466.
271. Sauer, H., Rosenblad, C., and Bjorklund, A. (1995). Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc. Natl. Acad. Sci. U.S.A. 92, 8935-8939. doi: 10.1073/pnas.92.19.8935.
272. Savola, J. M., Hill, M., Engstrom, M., Merivuori, H., Wurster, S., McGuire, S. G., et al. (2003). Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov. Disord. 18, 872-883. doi: 10.1002/mds.10464.
273. Schapira, A. H. (2011). Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs 25, 1061-1071. doi: 10.2165/11596310-000000000-00000.
274. Scholtissen, B., Verhey, F. R., Steinbusch, H. W., and Leentjens, A. F. (2006). Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data. J. Neural. Transm. 113, 59-73. doi: 10.1007/s00702-005-0368-3.
275. Schuster, S., Doudnikoff, E., Rylander, D., Berthet, A., Aubert, I., Ittrich, C., et al. (2009). Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol. Psychiatry. 65, 518-526. doi: 10.1016/j.biopsych.2008.09.008.
276. Shachar, D. B., Kahana, N., Kampel, V., Warshawsky, A., and Youdim, M. B. (2004). Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 46, 254-263. doi: 10.1016/j.neuropharm.2003.09.005.
277. Sherer, T. B., Betarbet, R., Kim, J. H., and Greenamyre, J. T. (2003). Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci. Lett. 341, 87-90. doi: 10.1016/S0304-3940(03)00172-1.
278. Shiozaki, S., Ichikawa, S., Nakamura, J., Kitamura, S., Yamada, K., and Kuwana, Y. (1999). Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl.) 147, 90-95. doi: 10.1007/s002130051146.
279. Silverdale, M. A., Nicholson, S. L., Crossman, A. R., and Brotchie, J. M. (2005). Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. Mov. Disord. 20, 403-409. doi: 10.1002/mds.20345.
280. Simola, N., Morelli, M., and Carta, A. R. (2007). The 6-hydroxydopamine model of Parkinson's disease. Neurotox. Res. 11, 151-167. doi: 10.1007/BF03033565.
281. Simuni, T., Borushko, E., Avram, M. J., Miskevics, S., Martel, A., Zadikoff, C., et al. (2010). Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. Mov. Disord. 25, 2863-2866. doi: 10.1002/mds.23308.
282. Singh, S., Singh, K., Gupta, S. P., Patel, D. K., Singh, V. K., Singh, R. K., et al. (2009). Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum. Brain Res. 1283, 115-126. doi: 10.1016/j.brainres.2009.06.002.
283. Singleton, A. B., Farrer, M. J., and Bonifati, V. (2013). The genetics of Parkinson's disease: progress and therapeutic implications. Mov. Disord. 28, 14-23. doi: 10.1002/mds.25249.
284. Slevin, J. T., Gash, D. M., Smith, C. D., Gerhardt, G. A., Kryscio, R., Chebrolu, H., et al. (2007). Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J. Neurosurg. 106, 614-620. doi: 10.3171/jns.2007.106.4.614.
285. Smeyne, R. J., and Jackson-Lewis, V. (2005). The MPTP model of Parkinson's disease. Brain Res. Mol. Brain Res. 134, 57-66. doi: 10.1016/j.molbrainres.2004.09.017.
286. Soriano, A., Ventura, R., Molero, A., Hoen, R., Casado, V., Cortes, A., et al. (2009). Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers. J. Med. Chem. 52, 5590-5602. doi: 10.1021/jm900298c.
287. Sprenger, F., and Poewe, W. (2013). Management of motor and non-motor symptoms in Parkinson's disease. CNS Drugs 27, 259-272. doi: 10.1007/s40263-013-0053-2.
288. Srivastava, R., Brouillet, E., Beal, M. F., Storey, E., and Hyman, B. T. (1993). Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: a stereological estimate of neuronal loss. Neurobiol. Aging. 14, 295-301. doi: 10.1016/0197-4580(93)90114-Q.
289. St-Pierre, J. A., and Bedard, P. J. (1995). Systemic administration of the NMDA receptor antagonist MK-801 potentiates circling induced by intrastriatal microinjection of dopamine. Eur. J. Pharmacol. 272, 123-129. doi: 10.1016/0014-2999(94)00612-B.
290. Stacy, M., Silver, D., Mendis, T., Sutton, J., Mori, A., Chaikin, P., et al. (2008). A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 70, 2233-2240. doi: 10.1212/01.wnl.0000313834.22171.17.
291. Stark, A. K., and Pakkenberg, B. (2004). Histological changes of the dopaminergic nigrostriatal system in aging. Cell. Tissue. Res. 318, 81-92. doi: 10.1007/s00441-004-0972-9.
292. Steece-Collier, K., Chambers, L. K., Jaw-Tsai, S. S., Menniti, F. S., and Greenamyre, J. T. (2000). Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp. Neurol. 163, 239-243. doi: 10.1006/exnr.2000.7374.
293. Stocchi, F., Rascol, O., Destee, A., Hattori, N., Hauser, R. A., Lang, A. E., et al. (2013). AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov. Disord. 28, 1838-1846. doi: 10.1002/mds.25561.
294. Striessnig, J., Koschak, A., Sinnegger-Brauns, M. J., Hetzenauer, A., Nguyen, N. K., Busquet, P., et al. (2006). Role of voltage-gated L-type Ca2+ channel isoforms for brain function. Biochem. Soc. Trans. 34, 903-909. doi: 10.1042/BST0340903.
295. Sulzer, D. (2007). Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends. Neurosci. 30, 244-250. doi: 10.1016/j.tins.2007.03.009.
296. Teismann, P., and Ferger, B. (2001). Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39, 167-174. doi: 10.1002/1098-2396(200102)39:2<167::AID-SYN8>3.0.CO;2-U.
297. The Ninds Net-Pd Investigators. (2006). A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66, 664-671. doi: 10.1212/01.wnl.0000201252.57661.e1.
298. The Ninds Net-Pd Investigators. (2008). A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin. Neuropharmacol. 31, 141-150. doi: 10.1097/WNF.0b013e3181342f32.
299. Thomas, A., Iacono, D., Luciano, A. L., Armellino, K., Di Iorio, A., and Onofrj, M. (2004). Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 75, 141-143..
300. Thrash, B., Uthayathas, S., Karuppagounder, S. S., Suppiramaniam, V., and Dhanasekaran, M. (2007). Paraquat and maneb induced neurotoxicity. Proc. West. Pharmacol. Soc. 50, 31-42..
301. Tomac, A., Lindqvist, E., Lin, L. F., Ogren, S. O., Young, D., Hoffer, B. J., et al. (1995). Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373, 335-339. doi: 10.1038/373335a0.
302. Traynelis, S. F., Wollmuth, L. P., Mcbain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., et al. (2010). Glutamate receptor ion channels: structure, regulation, and function. Pharmacol. Rev. 62, 405-496. doi: 10.1124/pr.109.002451.
303. Trevitt, J., Vallance, C., Harris, A., and Goode, T. (2009). Adenosine antagonists reverse the cataleptic effects of haloperidol: implications for the treatment of Parkinson's disease. Pharmacol. Biochem. Behav. 92, 521-527. doi: 10.1016/j.pbb.2009.02.001.
304. Turski, L., Bressler, K., Rettig, K. J., Loschmann, P. A., and Wachtel, H. (1991). Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349, 414-418. doi: 10.1038/349414a0.
305. Varanese, S., Howard, J., and Di Rocco, A. (2010). NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease. Mov. Disord. 25, 508-510. doi: 10.1002/mds.22917.
306. Varani, K., Vincenzi, F., Tosi, A., Gessi, S., Casetta, I., Granieri, G., et al. (2010). A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease. FASEB J. 24, 587-598. doi: 10.1096/fj.09-141044.
307. Verhagen Metman, L., Del Dotto, P., Van Den Munckhof, P., Fang, J., Mouradian, M. M., and Chase, T. N. (1998). Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50, 1323-1326. doi: 10.1212/WNL.50.5.1323.
308. Vernon, A. C., Palmer, S., Datla, K. P., Zbarsky, V., Croucher, M. J., and Dexter, D. T. (2005). Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. Eur. J. Neurosci. 22, 1799-1806. doi: 10.1111/j.1460-9568.2005.04362.x.
309. Vernon, A. C., Zbarsky, V., Datla, K. P., Croucher, M. J., and Dexter, D. T. (2007). Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. J. Neurochem. 103, 1075-1091. doi: 10.1111/j.1471-4159.2007.04860.x.
310. Vissel, B., Krupp, J. J., Heinemann, S. F., and Westbrook, G. L. (2001). A use-dependent tyrosine dephosphorylation of NMDA receptors is independent of ion flux. Nat. Neurosci. 4, 587-596. doi: 10.1038/88404.
311. Wachtel, H., Kunow, M., and Loschmann, P. A. (1992). NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats. Neurosci. Lett. 142, 179-182. doi: 10.1016/0304-3940(92)90368-H.
312. Wachter, B., Schurger, S., Rolinger, J., Von Ameln-Mayerhofer, A., Berg, D., Wagner, H. J., et al. (2011). Effect of 6-hydroxydopamine (6-OHDA) on proliferation of glial cells in the rat cortex and striatum: evidence for de-differentiation of resident astrocytes. Cell. Tissue. Res. 342, 147-160. doi: 10.1007/s00441-010-1061-x.
313. Wang, L., Muramatsu, S., Lu, Y., Ikeguchi, K., Fujimoto, K., Okada, T., et al. (2002). Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene. Ther. 9, 381-389. doi: 10.1038/sj.gt.3301682.
314. Weidong, L., Shen, C., and Jankovic, J. (2009). Etiopathogenesis of Parkinson disease: a new beginning? Neuroscientist 15, 28-35. doi: 10.1177/1073858408319974.
315. Wilson, C. J., and Callaway, J. C. (2000). Coupled oscillator model of the dopaminergic neuron of the substantia nigra. J. Neurophysiol. 83, 3084-3100..
316. Wiltgen, B. J., Royle, G. A., Gray, E. E., Abdipranoto, A., Thangthaeng, N., Jacobs, N., et al. (2010). A role for calcium-permeable AMPA receptors in synaptic plasticity and learning. PLoS ONE 5:12818. doi: 10.1371/journal.pone.0012818.
317. Wolf, E., Seppi, K., Katzenschlager, R., Hochschorner, G., Ransmayr, G., Schwingenschuh, P., et al. (2010). Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov. Disord. 25, 1357-1363. doi: 10.1002/mds.23034.
318. Wright, A., and Vissel, B. (2012). The essential role of AMPA receptor GluR2 subunit RNA editing in the normal and diseased brain. Front. Mol. Neurosci. 5:34. doi: 10.3389/fnmol.2012.00034.
319. Wu, T., Wang, J., Wang, C., Hallett, M., Zang, Y., Wu, X., et al. (2012). Basal ganglia circuits changes in Parkinson's disease patients. Neurosci. Lett. 524, 55-59. doi: 10.1016/j.neulet.2012.07.012.
320. Wullner, U., Testa, C. M., Catania, M. V., Young, A. B., and Penney, J. B. Jr. (1994). Glutamate receptors in striatum and substantia nigra: effects of medial forebrain bundle lesions. Brain Res. 645, 98-102. doi: 10.1016/0006-8993(94)91642-X.
321. Xu, K., Xu, Y. H., Chen, J. F., and Schwarzschild, M. A. (2002). Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci. Lett. 322, 13-16. doi: 10.1016/S0304-3940(02)00069-1.
322. Yasuda, Y., Shimoda, T., Uno, K., Tateishi, N., Furuya, S., Yagi, K., et al. (2008). The effects of MPTP on the activation of microglia/astrocytes and cytokine/chemokine levels in different mice strains. J. Neuroimmunol. 204, 43-51. doi: 10.1016/j.jneuroim.2008.08.003.
323. Youdim, M. B. (2012). M30, a brain permeable multitarget neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models. Parkinsonism. Relat. Disord. 18(Suppl. 1), S151-S154. doi: 10.1016/S1353-8020(11)70047-5.
324. Youdim, M. B., Stephenson, G., and Ben Shachar, D. (2004). Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann. N.Y. Acad. Sci. 1012, 306-325. doi: 10.1196/annals.1306.025.
325. Zarow, C., Lyness, S. A., Mortimer, J. A., and Chui, H. C. (2003). Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60, 337-341. doi: 10.1001/archneur.60.3.337.
326. Zhang, Z., Miyoshi, Y., Lapchak, P. A., Collins, F., Hilt, D., Lebel, C., et al. (1997). Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J. Pharmacol. Exp. Ther. 282, 1396-1401..
327. Zhou, F. C., Bledsoe, S., and Murphy, J. (1991). Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res. 556, 108-116. doi: 10.1016/0006-8993(91)90553-8.
328. Zuddas, A., Oberto, G., Vaglini, F., Fascetti, F., Fornai, F., and Corsini, G. U. (1992a). MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates. J. Neurochem. 59, 733-739. doi: 10.1111/j.1471-4159.1992.tb09429.x.
329. Zuddas, A., Vaglini, F., Fornai, F., Fascetti, F., Saginario, A., and Corsini, G. U. (1992b). Pharmacologic modulation of MPTP toxicity: MK 801 in prevention of dopaminergic cell death in monkeys and mice. Ann. N.Y. Acad. Sci. 648, 268-271. doi: 10.1111/j.1749-6632.1992.tb24553.x